Clinical trials
Recurrent WHO Grade 3 Glioma clinical trials
Below are recruiting recurrent who grade 3 glioma clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06712875RecruitingPhase 1/Phase 2
Brain cancer drug combo for kids with BRAF mutations
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
Washington D.C., District of ColumbiaAges 1–26 - NCT06666712RecruitingPhase 1
Chronic brain infusion of topotecan for recurrent glioma
This trial tests a treatment called topotecan that is delivered directly into the brain through a small tube (convection-enhanced delivery). It is for people whose IDH-mutant glioma has come back despite standard treatment. The goal is to see if this approach can help control the tumor.
New York, New YorkAges 18 years+ - NCT06482905RecruitingPhase 1
CAR-T cell therapy for recurrent grade 4 brain tumors
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
Phoenix, ArizonaAges 18–75 - NCT06444412RecruitingPhase 2
Testing a new PET scan to detect brain tumor recurrence
This trial tests a special imaging scan called Ga-68 PSMA-11 PET/CT to see if it can better detect when a glioma brain tumor has come back or progressed. It is for people who have already had standard treatment and are planning surgery for a suspected recurrence.
Rochester, MinnesotaAges 18 years+ - NCT06410248RecruitingPhase 1
Triapine with temozolomide for recurrent glioblastoma
This trial is testing a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back. The goal is to see if this combination can help control the tumor.
Chicago, IllinoisAges 18 years+ - NCT06397560Recruiting
Proton radiation for returning brain tumors
This trial tests a new type of proton radiation therapy given at a lower dose rate to treat brain tumors that have come back after previous radiation. The goal is to see if it's safe and effective.
Boca Raton, FloridaAges 18 years+ - NCT05532397Recruiting
Tested lab-chosen drug combo for recurrent brain tumor
This study uses a patient’s tumor tissue to test drug combinations in the lab, aiming to help choose a better second-line treatment for recurrent high-grade astrocytic glioma. If your tumor tissue can be tested, the results may guide a more personalized medication plan.
SingaporeAges 21–99 - NCT05698524RecruitingPhase 1
Temodar plus an investigational pill for recurrent brain cancer
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
Omaha, NebraskaAges 19 years+ - NCT05609994RecruitingPhase 1
Vorasidenib plus a peptide vaccine for recurrent low-grade glioma
This Phase 1 study tests vorasidenib combined with a personalized tumor-targeting peptide vaccine in adults with a specific type of recurrent brain tumor. It aims to see how safe the combination is and whether it can help slow the tumor’s growth.
Durham, North CarolinaAges 18 years+ - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Birmingham, AlabamaAges 18 years+ - NCT05096481RecruitingPhase 2
Vaccine for brain tumors in children and young adults
This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.
Aurora, ColoradoAges 3–39 - NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Birmingham, AlabamaAges 2–39 - NCT04923126RecruitingPhase 1/Phase 2
Mirdametinib for children with low-grade brain tumors
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Memphis, TennesseeAges 2–24 - NCT04732065RecruitingPhase 1
ONC206 for certain brain tumors in children and young adults
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
San Francisco, CaliforniaAges 2–21 - NCT04540107RecruitingPhase 1
MRI scan study to characterize lower-grade brain tumors
This Phase 1 study uses special MRI scans (including a form of MR spectroscopy) to better understand lower-grade gliomas. It is designed to test how well the imaging can “characterize” the tumor and to improve understanding for treatment planning.
San Francisco, CaliforniaAges 18 years+ - NCT04573140RecruitingPhase 1
RNA vaccine study for newly diagnosed adult and pediatric brain tumors
This Phase 1 trial studies an “RNA-lipid particle” vaccine given after surgery for certain newly diagnosed brain cancers (glioblastoma in adults, high-grade glioma in children/teens). The goal is to see whether the vaccine is safe and can train the immune system to fight the tumor.
Washington D.C., District of ColumbiaAges 4 years+ - NCT04485559RecruitingPhase 1
Trametinib and everolimus for recurrent gliomas
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Birmingham, AlabamaAges 1–25 - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT06072586RecruitingEarly Phase 1
Study of BDTX-1535 for brain tumors with EGFR changes
This trial tests a new drug, BDTX-1535, for people with a type of brain tumor called high-grade glioma that has a specific change in the EGFR gene. The study looks at how the drug works in the body and how safe it is for both newly diagnosed and recurrent tumors.
Chandler, ArizonaAges 18 years+ - NCT06330337RecruitingPhase 3
Electroacupuncture plus paclitaxel for recurrent high-grade glioma
This trial tests whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to the chemotherapy drug paclitaxel can help people with recurrent high-grade glioma. The goal is to see if the combination works better than paclitaxel alone.
ZhejiangAges 18–70 - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT06428045RecruitingPhase 1
STARLITE for hard-to-surgery high-grade brain tumors
This trial tests a new treatment called STARLITE for people with fast-growing brain tumors (high-grade gliomas) that cannot be safely removed with surgery. The treatment uses a laser to destroy the tumor from the inside. It may be a good option if you haven't had any prior treatment for this tumor.
Miami, FloridaAges 18 years+ - NCT05660369RecruitingPhase 1
CAR T-cell treatment for EGFR-mutant glioblastoma
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
Boston, MassachusettsAges 18 years+
Hear when a new Recurrent WHO Grade 3 Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent who grade 3 glioma?
- Yes. Clin2 currently lists 93 recruiting recurrent who grade 3 glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent who grade 3 glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent who grade 3 glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.